Xeris Biopharma Holdings, Inc. hosted its first Analyst and Investor Day, where it unveiled a comprehensive strategy for long-term growth and value creation. The company reaffirmed its full-year 2025 total revenue guidance of $260 million to $275 million and reiterated its commitment to maintaining positive adjusted EBITDA. This strategic roadmap builds on the company's foundation of innovation and commercial success.
During the event, Xeris provided an ambitious long-range financial outlook, targeting $750 million in total revenue by 2030. The company also projected that Recorlev, its therapy for Cushing's syndrome, could achieve nearly $1 billion in net revenue by 2035. These targets underscore the significant growth potential seen in its commercial portfolio.
A key highlight was the projected potential of XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, which is anticipated to become a $1 billion to $3 billion peak net revenue product. This pipeline asset is expected to be a transformative opportunity, leveraging Xeris's existing endocrinology infrastructure for efficient market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.